News
EBR to Raise A$150m via Fully Underwritten Capital Raising
Listcorp carries an ASX announcement in which EBR Systems flags a fully underwritten capital raising; the page shows only the headline, with no body text or further detail.
Startup · $60m raised
EBR Systems
Silicon Valley
Funding history
-
IPO
-
Unnamed stage : $30,000,000+
-
Unnamed stage : $30,000,000
Investors
Every investor coverage indicates participated in a round EBR Systems raised.
| Investor | Rounds | Invested |
|---|---|---|
| Ascension Ventures | Unnamed stage | - |
| Brandon Capital | Unnamed stage | - |
| Brandon Capital Partners | Unnamed stage | - |
| Emergent Medical Partners | Unnamed stage | - |
| HESTA | Unnamed stage | - |
| Hostplus | Unnamed stage | - |
| M.H. Carnegie | Unnamed stage | - |
| M.H. Carnegie & Co | Unnamed stage | - |
| Split Rock Partners | Unnamed stage | - |
| TelstraSuper | Unnamed stage | - |
On a portfolio page
Investors whose own portfolio pages list EBR Systems, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon BioCatalyst | its portfolio page ↗ |
Who bought EBR Systems
The transaction that ended EBR Systems's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| - | IPO | 24 Nov 2021 | $110m | Brandon BioCatalyst, Brandon Capital, Brandon Capital portfolio, Brandon BioCatalyst portfolio |
What EBR Systems bought
Companies EBR Systems acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
People
Coverage
Stories naming EBR Systems. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Funding announcement
Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close totalling over A$430 m
Brandon Capital has completed a A$439 million final close for its sixth life sciences fund, bringing the National Reconstruction Fund Corporation and WA Government in alongside backers such as HESTA, Hostplus, CSL and QIC.
News
World-First FDA Approval for EBR Systems' Leadless Cardiac Device Opens US$3.6bn Market
Cardiac device maker EBR Systems has won US regulator clearance for its leadless heart-failure therapy, clearing the way for staged commercial release later in 2025 and broader distribution in 2026.
News
FDA Approves WiSE® System, World's First and Only Leadless Left Ventricular Endocardial Pacing (LVEP) Device for CRT
EBR Systems has won US regulatory approval for its WiSE implant, the first leadless device for a form of cardiac resynchronization therapy, which the CEO frames as the end of a 22-year development phase.
Unnamed stage
$30m+
EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation
Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.
Funding announcement
Silicon Valley pacemaker hopes to capture Aussie hearts with ASX float
US-based leadless pacemaker maker EBR Systems has listed on the ASX, spurning US SPAC offers thanks to its local investor base; Blackbird's earlier investment in Vexev is also noted.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio
Funding announcement
World's First Leadless Left Bundle Branch Area Pacing Implant Utilizing EBR Systems' WiSE CRT System
A French cardiac specialist performed the first leadless left bundle branch area pacing implant using EBR Systems' wireless pacing device, with the announcement recalling the company's private equity backers.
6 deals
Brandon Capital news
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Cut Through Venture·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·Forbes Australia·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com·Forbes Australia
Funding announcement
FDA Grants EBR Systems Breakthrough Device Designation Status for the WiSE Cardiac Resynchronization Therapy (CRT) System
EBR Systems' wireless cardiac pacing system won FDA Breakthrough Device Designation, bringing priority review, while its SOLVE CRT pivotal trial enrolls heart failure patients; the company counts Brandon Capital among its backers.
Unnamed stage
$30m
EBR Systems Closes $30M in New Funding, John McCutcheon Joins Company as President and CEO
Cardiac pacing developer EBR Systems has completed a $30 million financing co-led by two Australian investors to finish its clinical trial, and has appointed John McCutcheon as president and chief executive.
2 deals
Brandon Capital Partners launches new Medical Research Commercialisation Fund, seeks NZ institutional
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily